CardioMech

About:

CardioMech develops devices for structural heart disease, offering alternatives to cardiac surgery, specifically for mitral valve issues.

Website: https://www.cardiomech.com

Top Investors: Investinor, Hadean Ventures

Description:

CardioMech is a developer of therapeutic devices for structural heart disease that provides a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve. The company's devices are used for the placement of artificial chords, enabling surgeons to get access to new therapeutic options for heart diseases. The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail. CardioMech was founded in 2015 and is headquartered in Trondheim, Norway.

Total Funding Amount:

$54.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Trondheim, Sor-Trondelag, Norway

Founded Date:

2015-01-01

Contact Email:

info(AT)cardiomech.com

Founders:

Jacob Bergsland, Nikolai Hiorth

Number of Employees:

1-10

Last Funding Date:

2024-01-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai